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Objective: The objective of this study was to determine the impact of blood sample timing 
on the diagnosis of subclinical thyroid dysfunction (SCTD) and mortality in patients with 
acute myocardial infarction (AMI).  
Patients, Design and Main Outcome Measures: Patients with AMI had thyroid function 
evaluated on admission between December 2014 and December 2016 and those with 
abnormal serum TSH had repeat thyroid function assessed at least a week later. The 
association between sample timing and SCTD was evaluated by logistic regression analysis. 
Secondary outcomes were confirmation of SCTD on repeat testing and all-cause mortality 
up to June 2018.  
Results: Of the 1806 patients [29.2% women, mean (SD) age of 64.2 (12.1) years] 
analysed, the prevalence of subclinical hypothyroidism (SCH) was 17.2% (n=311) and 
subclinical hyperthyroidism (SHyper) was 1.2% (n=22) using a uniform TSH reference 
interval. The risk of being diagnosed with SCTD varied by sample timing in fully-adjusted 
models. The risk of SCH was highest between 00:01–06:00hrs and lowest between 12:01–
18:00hrs, p for trend <0.001, and risk of SHyper was highest between 12:01-18:00hrs and 
lowest between 00:01-06:00hrs. Furthermore, time of the initial sample was associated with 
the risk of remaining in a SCH state subsequently. Mortality in SCH patients was not 
elevated when a uniform TSH reference interval was utilised. However, when time-period-
specific TSH reference ranges were utilised, the mortality risk was significantly higher in SCH 























Conclusions: Sample timing impacts on the diagnosis and prognosis of SCH in AMI patients. 
If sample timing is not accounted for, SCH is systemically misclassified, and its measurable 
influence on mortality is lost.  
Keywords: Thyroid function, sample timing, acute myocardial infarction, mortality 
 
Précis 
We analyzed thyroid function sample timing in patients with acute myocardial infarction 
and found that sample timing effects the diagnosis of subclinical thyroid dysfunction and 

























The diagnosis of subclinical thyroid dysfunction (SCTD) is established on the basis of 
abnormal serum thyrotropin (TSH) levels and when circulating thyroid hormone (thyroxine 
and triiodothyronine) concentrations are within the reference range. The log-linear 
relationship between TSH and thyroid hormones means that even minor alterations in 
thyroid hormones leads to an amplified TSH response.1 Therefore, a persistent TSH value 
outside its reference range indicates that thyroid hormones are abnormal for the given 
individual even if the levels of the thyroid hormones themselves lie within the normal range. 
Thus, an abnormal serum TSH measurement is essential in establishing a diagnosis of 
primary thyroid dysfunction and, furthermore, it implies that SCTD may be defined purely in 
biochemical terms. Subclinical hypothyroidism (SCH) and subclinical hyperthyroidism 
(SHyper) have a prevalence ranging between 5–18% and 0.1–2%, respectively,2 and both are 
associated with cardiovascular diseases as well as mortality in some but not all studies.3,4 
Furthermore, SCTD in patients admitted with acute coronary syndromes has been linked to 
adverse outcomes.5,6  
Serum TSH is affected by a number of factors including age, gender, ethnicity, smoking 
status, body mass index, iodine status, thyroid peroxidase antibody (TPOAb) status, the type 
of assay used, drugs and concurrent illnesses.7 Sample timing also has an important effect 
on serum TSH levels with a recognised circadian rhythm in serum TSH in healthy individuals 
reaching peak levels in the early hours of the morning and nadir in the afternoon (8). Most 
studies that have investigated the effect of sample timing on serum TSH and thyroid 
hormones have been in small groups of healthy volunteers and have shown a mild but 























secretion has been found to be diminished or absent in a variety of circumstances, including 
patients with critical illness, Alzheimer’s disease, other endocrinopathies, and during 
periods of fasting.9 It has been generally accepted that the circadian fluctuation of serum 
TSH and thyroid hormones contributes to the width of their respective reference ranges but 
does not substantially affect the diagnosis of SCTD.10 Nevertheless, a recent retrospective 
analysis from a large laboratory database suggests that the upper limit of serum TSH levels 
is influenced by the sample timing time as well as age.11 It is unknown whether sample 
timing of thyroid function in patients presenting with acute myocardial infarction (AMI) 
impacts on the diagnosis of SCTD and subsequent adverse outcomes. We analysed data 
from the multicentre ThyrAMI-1 study to investigate if sample timing impacts on the 




Participants: ThyrAMI-1 is a prospective study that recruited patients (n=1982) with both 
acute ST-elevation (STEMI) and non-ST-elevation (NSTEMI) myocardial infarction from six 
cardiac centres in England between December 2014 and December 2016.12 (Supplementary 
Figure 1).13 AMI was diagnosed using the standard third universal definition criteria.14 
Participants provided written informed consent and the research was approved by the UK 
National Research Ethics Service (reference number 14/NE/0151). The aim of the project 
was to investigate thyroid function in patients admitted with AMI from the first available 
blood sample soon after admission to hospital and to identify individuals with SCH to recruit 
to an interventional trial of treatment with levothyroxine (LT4) – the ThyrAMI-2 trial. In this 























hospital blood samples were analysed for routine clinical parameters and thyroid function 
was evaluated after the participant had provided consent. All samples were obtained prior 
to invasive coronary procedures. Participants who had samples for thyroid function 
obtained more than 24 hours after presentation (due to insufficient sample volume in the 
first available sample) were excluded from this analysis (n=48). In addition, patients with 
newly-diagnosed overt thyroid disease (n=6) and those on medications affecting thyroid 
function such as amiodarone, lithium and oral glucocorticoids (n=9) were excluded. 
Participants treated with LT4 (n=113), however, were included and a sensitivity analysis was 
conducted after their exclusion. Of the remainder, those with abnormal TSH values and 
normal thyroid hormone levels were classed as having SCTD. The time of blood sampling 
was acquired from the electronic laboratory database at each site and was defined as the 
time when the blood sample was collected (reported in hh:mm format). This information 
was not available for 39 participants and, for whom, time of sample receipt in each 
participating laboratory was utilised. The median time difference between sample collection 
and reception in the laboratory was 32 minutes. Patients that had evidence of SCTD on the 
initial sample (n=336) were invited to have their thyroid function repeated 7–10 days later 
between 08:00 and 10:00 hours to assess if the SCTD was persistent. Out of these, 275 
individuals agreed while another 33 participants had repeat testing via their General 
Practitioner (Family Physician). All repeat thyroid function tests utilised the same assay as 
the initial investigation.  
Mortality status was assessed for all participants up to 30th June 2018 by interrogating the 
National Health Service (NHS) Summary Care Records (SCR) that provides up to date life-























period was the date of the AMI and the end of follow-up was date of death or the date of 
ascertainment via the SCR.  
Laboratory measurements: Serum TSH, FT4 and FT3 as well as creatinine were analysed 
using either Roche eCobas (4 centres) or Advia Centaur (2 centres) immunoassays. The 
reference ranges for classifying normal thyroid parameters were uniformly set a priori 
across all sites irrespective of immunoassay method being used. The performance of both 
the Roche and Centaur assays for estimating TSH show very good agreement with a 
previous analysis demonstrating a regression co-efficient (95% confidence intervals) of 0.99 
(0.99 – 0.99).16 The reference ranges were: TSH 0.4–4.0 mU/L, FT4 10–25 pmol/L (0.78–1.94 
ng/dL), FT3 3.0–7.0 pmol/L (2.28–4.23 pg/mL). Anti-thyroid peroxidase antibody (TPOAb) 
was measured by Roche or Centaur immunoassays and levels below 35 mU/L were classed 
as negative. SCH was defined as raised serum TSH (>4.0 mU/L) with FT4 within the reference 
range and SHyper was defined as low serum TSH (<0.4 mU/L) with both FT4 and FT3 within 
their respective reference ranges.  
 
Statistical analyses: Continuous variables across time-periods were compared using ANOVA 
or Kruskal-Wallis (depending on normal or non-normal distribution, respectively) and 
categorical variables were compared by Fisher’s exact test. The relationship and the 
linearity between sample timing (as a continuous parameter from 1 to 1440 minutes – 
representing the number of minutes in 24 hours) and thyroid function parameters were 
examined using ordinary least squares regression with restricted cubic splines with three 
knots. Covariates for the multivariable models were selected based on clinical relevance or 
if known to affect serum TSH levels. Binary logistic regression analyses were performed 























time of sampling (in periods of 6 hours each). The relationship between SCTD and all-cause 
mortality was evaluated using Cox proportional hazards analysis. All analyses were adjusted 
for relevant variables such as age, gender, centre, smoking status (current, ex- or non-
smoker), body mass index (BMI), serum creatinine, type of AMI (STEMI or NSTEMI), pain to 
sampling time (calculated from onset of pain or symptoms of AMI till time of blood 
sampling), anti-TPOAb levels (as a continuous variable), history of ischemic heart disease 
(yes/no), hypertension (yes/no), diabetes mellitus (yes/no), cerebrovascular disease 
(yes/no), atrial fibrillation (yes/no) and hypothyroidism (yes/no). Assay type was not used as 
an additional covariate in these analyses as centre from where the participant was recruited 
(and their thyroid function measured) is already included. Lower and upper limits of time-
period-specific reference ranges for thyroid function parameters were calculated using the 
2.5th and the 97.5th percentile values, respectively, in patients not on LT4 treatment.17  
As higher serum TSH levels per se rather than time-period specific TSH abnormalities could 
be linked with mortality, we also examined the relationship between baseline serum TSH 
and mortality using Cox proportional hazards analysis after adjusting for the above-
mentioned variables.  
To ensure the validity of the results obtained, several sensitivity analyses were performed: 
analysing the relationship between sample timing and thyroid function parameters 
stratified by the thyroid function assays utilised, by LT4 use, and by type of AMI. The 
statistical software programmes SPSS v24.0 (Chic, Ill) and R (rms package, R project, 
Institute for Statistics and Mathematics, R Core Team, version 3.2.2) were utilised for 


























Prevalence of SCTD and baseline characteristics by time of sampling  
The baseline characteristics of participants for each time period are presented in Table 1. 
The median (IQR) time interval between onset of chest pain and blood sampling was 137 
(65–218) minutes. Clinical, biochemical and pre-existing medical conditions were similar 
across the various periods. However, there were less STEMI admissions in the 12:01–18:00 
hrs period than the other periods. In addition, serum TSH and FT3 were highest between 
00:01–06:00 hrs and lowest in the 12:01–18:00 period whereas there was no significant 
difference between FT4 levels. Consequently, the diagnosis of SCH was highest in the 00:01–
06:00 period (20.9%) and lowest in the 12:01–18:00 period (8.7%). Conversely, the 
prevalence of SHyper was lowest in the 00:01–06:00 period (0.7%) and highest in the period 
between 12:01–18:00 hrs (2.5%). When time-period specific TSH ranges were utilised 
(Supplementary Table 1)13, the prevalence of SCH reduced dramatically (n=49; 2.7%) 
whereas the frequency of SHyper participants increased slightly (n=37; 2%). Compared to 
the significant variation in frequency of both SCH and SHyper across various periods (Table 
1) the prevalence of both SCH and SHyper was similar across all periods when time-period 
specific TSH reference intervals were utilised (p=0.79). 
 
Sample timing and thyroid function parameters 
Time of sampling as a continuous variable over 24 hours (from 0 to 1440 minutes) was 
significantly associated with serum TSH and FT3 levels in an independent and nonlinear 
manner (Figure 1).  Serum TSH and FT3 levels were highest between 00:01-06:00 hrs and 
lowest between 12:01-18:00 hrs. No significant relationship was observed between time of 























between time of sampling and pain to sampling time on the various thyroid function 
parameters (all p values > 0.10). 
Sample timing and thyroid dysfunction  
There was a significant and non-linear association between time of sampling and risk of 
being diagnosed with SCH (p for non-linearity<0.0001). Restricted cubic spline analysis with 
3 knots confirmed that the risk of being diagnosed with SCTD varied with time of sampling.  
The risk of being diagnosed with SCH was higher in the 00:01-06:00 period and lower in the 
12:01=18:00 period (Figure 2A). The other independent predictors of SCH were increasing 
age, female gender, STEMI and positive TPOAb status.  
The risk of being diagnosed with SHyper was higher in the 12:01-18:00 period and lower in 
the 00:01-06:00 period (Figure 2B). In addition, a significant negative association was found 
between SHyper and BMI. 
 
Sample timing and risk of remaining in SCTD state 
A total of 308 patients with SCTD diagnosed on admission had repeat thyroid function 
assessed (n=290 and n=18 with baseline SCH and SHyper, respectively). Of these, 127 (44%) 
of individuals with SCH and 11 (61%) of participants with SHyper normalised serum TSH 
levels. There was a significant difference in normalisation rates depending on baseline time-
period of sampling. In the baseline SCH group, 58% of patients from 00:01–06:00 hrs 
normalised serum TSH on repeat testing whereas only 28% of those from 12:01–18:00 
normalised (p<0.001) (Figure 3). In the SHyper group at baseline, no statistical analysis was 
performed due to the small number of participants in each time-period. The one participant 























participants, of the 11 with repeat data available for the 12:01–18:00 hrs period normalised 
their TSH.  
 
In patients with SCH, baseline time of sampling was associated with the risk of remaining in 
the SCH state on repeat thyroid function testing. Individuals who had initial thyroid function 
test drawn between 12:01–18:00 hrs were more likely to remain in the SCH state than those 
who had initial sampling between 00:01–06:00 hrs [OR 2.56 (1.09 – 5.95)] or between 
18:01–00:00 hrs [OR 2.33 (1.01 – 5.26)]. Other variables that were significantly associated 
with remaining SCH were higher initial serum TSH level [OR 1.32 (1.13 – 1.55) and TPOAb 
positivity [OR 2.56 (1.67 – 3.58)]. 
 
All-cause mortality in relation to SCTD status determined using uniform or time-period 
specific TSH reference intervals. 
There were 168 mortality events over a median (IQR) follow-up period of 28 (23–34) 
months: 31 (9.9%) events in patients with SCH on admission and 135 (9.2%) events in 
euthyroid patients. When uniform TSH reference intervals were utilized, SCH was not 
associated with all-cause mortality (HR, 1.06; 95%CI, 0.69 – 1.62; p-value, 0.80). 
Furthermore, all-cause mortality in the SCH participants was not different across the various 
time periods (p for interaction between SCH and time-period = 0.34). There were 2 mortality 
events in the SHyper group over the follow-up period.  
However, mortality was significantly higher in SCH patients that were categorised using a 
time-period specific reference interval with HR of 2.26 (1.01 – 5.19), p=0.04. Mortality in the 
SHyper group was similar to euthyroid controls when time-period specific TSH reference 























SCTD patients who had persistent SCTD on repeat function (data not shown). There was no 
significant relationship between baseline serum TSH levels and mortality (p=0.76) 
(Supplementary Figure 2).13  
Sensitivity analysis: Several sensitivity analyses were performed to assess the validity of our 
results. First, we evaluated the relationship between thyroid function tests (TSH, FT4 and 
FT3) with time of sampling separately for the two immunoassays used (Roche and Centaur) 
and the results remained similar (Supplementary Table 2).13 Second, we assessed the 
relationship between thyroid function tests and time of sampling for the LT4 users and non-
users and found that the circadian rhythm of TSH and FT3 was not observed in LT4 users 
(Supplementary Table 3). Third, we investigated the association between thyroid function 
tests and time of sampling separately for STEMI and NSTEMI patients and found no 
difference (Supplementary Table 4).13 Fourth, we analysed the relationship between thyroid 
function tests and time of sampling after excluding those patients with type 2 diabetes who 
used metformin and this confirmed the circadian rhythm of serum TSH and FT3 levels 
although serum TSH levels tended to be slightly higher (data not shown). 
 
Discussion 
The results of this study have shown that the diagnosis of SCTD and subsequent rates of 
normalisation of serum TSH levels in patients with AMI is influenced by the time of 
sampling. Importantly, our data suggest that TSH levels higher than the time-period specific 
reference range are associated with increased mortality, and, crucially, this association was 
absent when standard TSH reference ranges are applied. These results contest the 























reference range and suggest that the time of sampling should be considered when 
evaluating whether a given TSH result is abnormal.  
 
Diurnal variation of serum TSH and, to a lesser extent, FT3 is recognised and is believed to 
contribute to the upper and lower limits of the reference range but is not considered to 
impact on the diagnosis of SCTD.18,19 This view is based on small studies of young healthy 
volunteers8 or patients with hypothyroidism20 and may not be applicable to the general 
population or, those with concurrent illness. The rise in nocturnal TSH levels is considered to 
be due to release of more immature form of TSH that is less bioactive.21 More recently, 
several retrospective analyses of tens of thousands of patients confirmed that the TSH 
concentrations or its reference interval varies significantly depending on the time of 
sampling.11,22,23   
 
An analysis of 47 patients with AMI demonstrated that mean TSH levels over 5 days were 
lower in non-survivors, possibly related to greater suppression of TSH by non-thyroidal 
illness.5 In another study involving cardiac patients, mild alterations in thyroid function, 
assessed within 2-5 days of hospital admission, were associated with worse prognosis, 
although patients with acute coronary syndromes were excluded.6 Another analysis of 
patients with acute coronary syndrome revealed that patients with high TSH levels 
(>4mU/L) had poorer outcomes.24 It is difficult to evaluate the true association of thyroid 
function with outcomes in these studies as TSH levels are affected by the illness as well as 
























Our analysis has several strengths. It is a prospective analysis of a large number of 
participants with AMI whose data were collected in a structured manner. Samples were 
obtained at the first opportunity after presentation to hospital (so the impact of non-
thyroidal illness was minimised) and prior to diagnostic coronary angiography (radiographic 
contrast contain iodine in supra-physiological amounts that could affect thyroid function).25 
Moreover, we also collected data on subsequent thyroid function in patients with initial 
SCTD in whom the repeat samples were collected at a uniform time-period. In addition, the 
analyses were adjusted for other confounding variables that could impact on TSH and 
thyroid hormone levels. Finally, there are no published data on mortality outcomes in 
relation to baseline thyroid function and time of sampling. Our analysis has some 
limitations. First, some of the thyroid function parameters were evaluated by a different 
assay. However, the two TSH immunoassays utilised are known to yield similar results16 and 
results were similar when analyses were performed separately for the two assays. Second, 
additional unaccounted variables (iodine intake, fasting and stress) or unmeasured 
parameters may have influenced our findings. Nevertheless, a wide variety of demographic, 
physical and biochemical factors were included in our multivariate regression analyses. 
Third, we did not have data available on recurrent cardiovascular events and nor does our 
analysis evaluate mechanisms as to how high serum TSH may adversely impact on mortality. 
Fourth, the number of individuals with SHyper (diagnosed using either standard TSH 
reference intervals or time-period specific reference ranges) are relatively low and the 
results obtained for this group should be interpreted with caution. Finally, our results were 
obtained from patients with AMI and cannot be generalizable to other acute conditions or 
to community-dwelling individuals in whom sampling for thyroid function is usually 























In conclusion, our results suggest that both the initial diagnosis of SCTD in patients with AMI 
and the proportion that subsequently normalise thyroid function is independently and 
significantly associated with time of sampling. Furthermore, mortality risk is similar in both 
SCH and euthyroid patients with AMI when uniform TSH reference ranges are utilised, as 
per current clinical practice, but, risk of mortality more than doubles when time-period 
specific TSH reference ranges are used to identify SCH. Our findings are important for 
interpretation of TSH levels in clinical practice. They suggest that for an accurate diagnosis 
of SCTD, the TSH reference range should take the time of sampling into account. 
Importantly, using this methodology to interpret the results may provide important 
prognostic information in patients after AMI.  
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Figure 1. The relationship between time of sampling over 24 hours and thyroid function 
parameters and TPOAb levels. 
Restricted cubic spline plots with three knots demonstrating the association of time of sampling (x axis) with the predicted mean thyroid 
function and TPOAb parameters (black lines) with 95% confidence intervals (grey area). All associations adjusted for age, sex, centre, body 
mass index, smoking status, type of AMI, pain to sampling time, serum creatinine, history of IHD, DM, CVD, BP, AF and hypothyroidism. 
 
Figure 2. Risk of being diagnosed with subclinical hypothyroidism (A) or subclinical 
hyperthyroidism (B) in relation to time of sampling.  
Restricted cubic spline curves with three knots of log relative odds risk of being diagnosed with subclinical hypothyroidism (SCH) (A) or 
subclinical hyperthyroidism (SHyper) (B) (black line) with 95% confidence intervals (grey areas) were plotted against time of sampling (24 
hour clock), adjusted for age, sex, centre, body mass index, smoking status, type of AMI (STEMI or NSTEMI), pain to sampling time, serum 
creatinine, TPOAb levels, history of ischaemic heart disease, diabetes mellitus, hypertension, cerebrovascular disease and atrial fibrillation. 
 
 
Figure 3. Time of sampling and the risk of remaining in subclinical hypothyroidism state. 
 
 
Figure 4. Hazard plots of all-cause mortality in relation to baseline thyroid status determined 
using uniform TSH reference intervals (A) or time-period specific TSH reference intervals (B).  
SCH = subclinical hypothyroidism, SHyper = subclinical hyperthyroidism. 
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Figure 4. Hazard plots of all-cause mortality in relation to baseline thyroid status determined using uniform TSH reference intervals (A) or time-period specific TSH reference intervals (B). 
No. at risk 
Euthyroid 1470 1403 1288 634              57 1720 1650 1512 743 59  
SCH 313 297       273 133 4 49 38 37 17
SHyper 23 23 22 6 1 37 34 33 12 3
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